Mouse Anti-Rat Ace Hybridoma [Alpha-BDF 4.2.2]

Objectives: The aim of the study is to adapt the Maladaptive Daydreaming Scale (MDS-16) to Hungarian, assess its psychometric properties, and establish its cut-off score. In addition, the relationship between maladaptive daydreaming and adverse childhood experiences was examined. Method: Study participants were recruited online via snowball sampling. Based on three inclusion criteria (self-identified MDer status; control over daydreaming; frequency of daydreaming) 160 out of 494 respondents were included in the study. Results: Our results confirm both the high reliability and convergent validity of the questionnaire. The cut-off score of 60 percentiles can reliably discriminate between excessive and normal daydreamers. The general applicability of the MDS-16-HU was tested and confirmed by the use of the Adverse Childhood Experience Questionnaire (ACE-10), a short, self-report questionnaire. Its results showed that certain types of childhood adversities increase the likelihood of maladaptive daydreaming. Conclusions: The instrument is a valid and reliable measure, therefore it can serve as a useful screening tool in clinical practice. In addition, our findings highlighted the role of childhood adversities in the aetiology of maladaptive daydreaming.

Dipeptidylpeptidase (DPP)-4 is a key regulator of the incretin system. For several years DPP-4 inhibitors in addition to GLP-1 analogues are of major importance in the clinical management of obesity and type 2 diabetes. DPP-4 is also known as CD26 and represents a membrane bound protease on the surface of several eukaryotic cell types. Of interest, DPP-4, like ACE2, has been shown to serve as a binding partner for corona-like viruses to enter host immune cells. Since metabolic diseases are major risk factors for the present COVID-19 pandemic, we examined circulating soluble DPP-4 serum concentrations in patients suffering from severe COVID-19 infection and in healthy human subjects in a case control design. In this analysis sDPP-4 levels were significantly lower in COVID-19 patients compared to controls (242.70 +/- 202.12 ng/mL versus 497.70 +/- 188.13 ng/mL, p = 0.02). We also examined sDPP-4 serum concentrations in patients suffering from sepsis not due to corona-like viruses. In these subjects, sDPP-4 levels were not different compared to healthy case controls (p = 0.14), which might suggest the decrease of sDPP-4 to be specific for corona-like virus infections. Currently, most data point towards membrane bound ACE2 in contrast to DPP-4 as the major binding partner for COVID-19 internalization into host immune cells. However, the finding that the circulating soluble form of DPP-4 is reduced in hospitalized patients might suggest a regulatory role for both, ACE and DPP-4, in COVID-19 infections, especially since obesity and type 2 diabetes are major risk factor for a severe course of the disease